| 000 | 01491 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513044157.0 | ||
| 264 | 0 | _c19950130 | |
| 008 | 199501s 0 0 eng d | ||
| 022 | _a0098-7484 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 245 | 0 | 0 |
_aEffects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. _h[electronic resource] |
| 260 |
_bJAMA _cJan 1995 |
||
| 300 |
_a199-208 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCholesterol, HDL _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEndometrial Hyperplasia _xchemically induced |
| 650 | 0 | 4 | _aEstrogen Replacement Therapy |
| 650 | 0 | 4 |
_aEstrogens, Conjugated (USP) _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinogen _xdrug effects |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 |
_aHeart Diseases _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin _xblood |
| 650 | 0 | 4 |
_aMedroxyprogesterone Acetate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPostmenopause _xdrug effects |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSystole _xdrug effects |
| 650 | 0 | 4 | _aWeight Gain |
| 773 | 0 |
_tJAMA _gvol. 273 _gno. 3 _gp. 199-208 |
|
| 999 |
_c7807015 _d7807015 |
||